165 related articles for article (PubMed ID: 20127006)
1. The knock-down of overexpressed EZH2 and BMI-1 does not prevent osteosarcoma growth.
Sasaki H; Setoguchi T; Matsunoshita Y; Gao H; Hirotsu M; Komiya S
Oncol Rep; 2010 Mar; 23(3):677-84. PubMed ID: 20127006
[TBL] [Abstract][Full Text] [Related]
2. The transcriptional repressor NIPP1 is an essential player in EZH2-mediated gene silencing.
Nuytten M; Beke L; Van Eynde A; Ceulemans H; Beullens M; Van Hummelen P; Fuks F; Bollen M
Oncogene; 2008 Feb; 27(10):1449-60. PubMed ID: 17724462
[TBL] [Abstract][Full Text] [Related]
3. The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens.
Steele JC; Torr EE; Noakes KL; Kalk E; Moss PA; Reynolds GM; Hubscher SG; van Lohuizen M; Adams DH; Young LS
Br J Cancer; 2006 Nov; 95(9):1202-11. PubMed ID: 17024127
[TBL] [Abstract][Full Text] [Related]
4. The Bmi-1 polycomb protein antagonizes the (-)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival.
Balasubramanian S; Adhikary G; Eckert RL
Carcinogenesis; 2010 Mar; 31(3):496-503. PubMed ID: 20015867
[TBL] [Abstract][Full Text] [Related]
5. Association of BMI1 with polycomb bodies is dynamic and requires PRC2/EZH2 and the maintenance DNA methyltransferase DNMT1.
Hernández-Muñoz I; Taghavi P; Kuijl C; Neefjes J; van Lohuizen M
Mol Cell Biol; 2005 Dec; 25(24):11047-58. PubMed ID: 16314526
[TBL] [Abstract][Full Text] [Related]
6. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
[TBL] [Abstract][Full Text] [Related]
7. The value of EZH2, p27(kip1), BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomy.
Wolters T; Vissers KJ; Bangma CH; Schröder FH; van Leenders GJ
BJU Int; 2010 Jul; 106(2):280-6. PubMed ID: 19888978
[TBL] [Abstract][Full Text] [Related]
8. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2.
Beke L; Nuytten M; Van Eynde A; Beullens M; Bollen M
Oncogene; 2007 Jul; 26(31):4590-5. PubMed ID: 17237810
[TBL] [Abstract][Full Text] [Related]
9. Enhancer of zeste homolog 2 silencing inhibits tumor growth and lung metastasis in osteosarcoma.
Lv YF; Yan GN; Meng G; Zhang X; Guo QN
Sci Rep; 2015 Aug; 5():12999. PubMed ID: 26265454
[TBL] [Abstract][Full Text] [Related]
10. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer.
Hoffmann MJ; Engers R; Florl AR; Otte AP; Muller M; Schulz WA
Cancer Biol Ther; 2007 Sep; 6(9):1403-12. PubMed ID: 18637271
[TBL] [Abstract][Full Text] [Related]
11. HDAC inhibitors repress the polycomb protein BMI1.
Grant S
Cell Cycle; 2010 Jul; 9(14):2705-6. PubMed ID: 20676031
[No Abstract] [Full Text] [Related]
12. Histone H3 modifications associated with differentiation and long-term culture of mesenchymal adipose stem cells.
Noer A; Lindeman LC; Collas P
Stem Cells Dev; 2009 Jun; 18(5):725-36. PubMed ID: 18771397
[TBL] [Abstract][Full Text] [Related]
13. FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells.
Du J; Li L; Ou Z; Kong C; Zhang Y; Dong Z; Zhu S; Jiang H; Shao Z; Huang B; Lu J
Breast Cancer Res Treat; 2012 Jan; 131(1):65-73. PubMed ID: 21465172
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic repression of SATB1 by polycomb group protein EZH2 in epithelial cells.
Lei L; Lu L; Xiang L; Xue-song W; De-pei L; Chih-chuan L
Chin Med Sci J; 2010 Dec; 25(4):199-205. PubMed ID: 21232178
[TBL] [Abstract][Full Text] [Related]
15. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation.
Fujii S; Ito K; Ito Y; Ochiai A
J Biol Chem; 2008 Jun; 283(25):17324-32. PubMed ID: 18430739
[TBL] [Abstract][Full Text] [Related]
16. The phosphatase interactor NIPP1 regulates the occupancy of the histone methyltransferase EZH2 at Polycomb targets.
Van Dessel N; Beke L; Görnemann J; Minnebo N; Beullens M; Tanuma N; Shima H; Van Eynde A; Bollen M
Nucleic Acids Res; 2010 Nov; 38(21):7500-12. PubMed ID: 20671031
[TBL] [Abstract][Full Text] [Related]
17. Fuse-binding protein 1 is a target of the EZH2 inhibitor GSK343, in osteosarcoma cells.
Xiong X; Zhang J; Liang W; Cao W; Qin S; Dai L; Ye D; Liu Z
Int J Oncol; 2016 Aug; 49(2):623-8. PubMed ID: 27278257
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma.
Yamaguchi J; Sasaki M; Sato Y; Itatsu K; Harada K; Zen Y; Ikeda H; Nimura Y; Nagino M; Nakanuma Y
Cancer Sci; 2010 Feb; 101(2):355-62. PubMed ID: 19860841
[TBL] [Abstract][Full Text] [Related]
19. EZH2 methyltransferase and H3K27 methylation in breast cancer.
Yoo KH; Hennighausen L
Int J Biol Sci; 2012; 8(1):59-65. PubMed ID: 22211105
[TBL] [Abstract][Full Text] [Related]
20. HDAC inhibitors conquer Polycomb proteins.
Yaswen P
Cell Cycle; 2010 Jul; 9(14):2705. PubMed ID: 20676029
[No Abstract] [Full Text] [Related]
[Next] [New Search]
